Purpose
Guide health care providers in determining recommended vaccines for each age group.
How to use the schedule
To make vaccination recommendations, healthcare providers should:
- Determine recommended vaccine by age (Table 1 - By Age)
- Assess need for additional recommended vaccinations by medical condition or other indication (Table 2 - By Medical Condition)
- Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
- Review new or updated ACIP guidance (Addendum)
Ages 19 Years or Older
| Recommended vaccination for adults who meet age requirement, lack documentation of vaccination, or lack evidence of immunity | Recommended vaccination for adults with an additional risk factor or another indication | Recommended vaccination based on shared clinical decision-making | No Guidance/Not Applicable |
| Vaccine | 19-26 years | 27-49 years | 50-64 years | ≥65 years | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
COVID-19  |
1 or more doses of 2024–2025 vaccine (See Notes) | 2 or more doses of 2024-2025 vaccine (See Notes) |
||||||||||||
| Influenza inactivated (IIV3, ccIIV3) Influenza recombinant (RIV3) |
1 dose annually | 1 dose annually (HD–IIV3, RIV3, or aIIV3 preferred) |
||||||||||||
| Influenza inactivated (aIIV3; HD–IIV3) Influenza recombinant (RIV3) |
Solid organ transplant (See Notes) | |||||||||||||
| Influenza live, attenuated (LAIV3) |
1 dose annually | |||||||||||||
| Respiratory Syncytial Virus (RSV) |
Seasonal administration during pregnancy.
(See Notes) |
|
≥75 years | |||||||||||
| Tetanus, diphtheria, pertussis (Tdap or Td) |
1 dose Tdap each pregnancy; 1 dose Td/Tdap for wound management (See Notes) | |||||||||||||
| 1 dose Tdap, then Td or Tdap booster every 10 years | ||||||||||||||
| Measles, mumps, rubella (MMR) |
1 or 2 doses depending on indication (if born in 1957 or later) |
|
||||||||||||
| Varicella (VAR) |
|
2 doses | ||||||||||||
| Zoster recombinant (RZV) |
2 doses for immunocompromising conditions (See Notes) |
2 doses | ||||||||||||
| Human papillomavirus (HPV) |
2 or 3 doses depending on age at initial vaccination or condition | 27 through 45 years | ||||||||||||
| Pneumococcal (PCV15, PCV20,PCV21, PPSV23) |
See Notes | |||||||||||||
| See Notes | ||||||||||||||
| Hepatitis A (HepA) |
2, 3, or 4 doses depending on vaccine | |||||||||||||
| Hepatitis B (HepB) |
|
|||||||||||||
| Meningococcal A, C, W, Y (MenACWY) |
1 or 2 doses depending on indication (See Notes for booster recommendations) | |||||||||||||
| Meningococcal B (MenB) |
2 or 3 doses depending on vaccine and indication (See Notes for booster recommendations) | |||||||||||||
| 19 through 23 years | ||||||||||||||
| Haemophilus influenzae type b (Hib) |
1 or 3 doses depending on indication | |||||||||||||
| Mpox |
2 doses | |||||||||||||
| Inactivated poliovirus (IPV) |
Complete 3-dose series if incompletely vaccinated. Self–report of previous doses acceptable (See Notes) | |||||||||||||
To make vaccination recommendations, healthcare providers should:
- Determine recommended vaccine by age (Table 1 - By Age)
- Assess need for additional recommended vaccinations by medical condition or other indication (Table 2 - By Medical Condition)
- Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
- Review contraindications and precautions for vaccine types (Appendix)
- Review new or updated ACIP guidance (Addendum)
Additional Information
This schedule is recommended by the Advisory Committee on Immunization Practices (ACIP) and approved by the Centers for Disease
Control and Prevention (CDC), American College of Physicians (ACP), American Academy of Family Physicians (AAFP), American College of Obstetricians and Gynecologists (ACOG), American College of Nurse-Midwives (ACNM), American Academy of Physician Associates (AAPA), American Pharmacists Association (APhA), and Society for Healthcare Epidemiology of America (SHEA).
Report
- Suspected cases of reportable vaccine-preventable diseases or outbreaks to your state or local health department
- Clinically significant adverse events to the Vaccine Adverse Event Reporting System (VAERS) at www.vaers.hhs.gov or (800-822-7967)
Questions or comments
Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.
Helpful information
- Complete Advisory Committee on Immunization Practices (ACIP) recommendations
- ACIP Shared Clinical Decision-Making Recommendations
- General Best Practice Guidelines for Immunization (including contraindications and precautions)
- Vaccine information statements
- Manual for the Surveillance of Vaccine-Preventable Diseases
(including case identification and outbreak response)